Highlights from ASCO GU 2017 - Results from #20

Viewing 21-40 of 100 articles

ASCO GU 2017: Evolution of circulating tumor DNA profile from 1st line to 2nd line therapy in metastatic renal cell carcinoma. - Session Highlights

ASCO GU 2017: Cryoablation of cT1 renal masses in the “healthy” patient: Early outcomes from Mayo Clinic. - Session Highlights

ASCO GU 2017: Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation. - Session Highlights

ASCO GU 2017: How best to treat locally advanced penile cancer: radiation versus surgery - Session Highlights

ASCO GU 2017: Orphan Cancers with Opportunities for Improved Treatment: Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy - Session Highlights

ASCO GU 2017: Phase II Study Supports Potential For Genentech’s TECENTRIQ® (ATEZOLIZUMAB) PLUS AVASTIN® (BEVACIZUMAB) For People With Locally Advanced or Metastatic Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses. - Session Highlights

ASCO GU 2017: Use of Ablation in Small Renal Tumors - Session Highlights

ASCO GU 2017: Novel Imaging Modality: Radiographic Biopsy - Session Highlights

ASCO GU 2017: Contemporary Role of Percutaneous Biopsy for the Small Renal Mass - Session Highlights

ASCO GU 2017: The Evolving Role of Active Surveillance in Small Renal Tumors - Session Highlights

ASCO GU 2017: Genetic Conditions With a Predisposition to Renal Cell Carcinoma - Session Highlights

ASCO GU 2017: Con: Is There a Role for Treatment Intensification for Patients With Poor Prognosis Germ-Cell Tumors With Unfavorable Marker Decline? - Session Highlights

ASCO GU 2017: Debate - Pro: Is There a Role for Treatment Intensification for Patients With Poor Prognosis Germ-Cell Tumors With Unfavorable Marker Decline? - Session Highlights

ASCO GU 2017: Actionable targets in germ cell tumors - Session Highlights

ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Urologic Oncology - Session Highlights

ASCO GU 2017: Best of journals: Renal Cell Carcinoma - Radiologist - Session Highlights

ASCO GU 2017: Quality of care in non-muscle invasive bladder cancer: optimizing surgical and medical therapies - Session Highlights

ASCO GU 2017: Intravesical rAD-IFNa/Syn3 for patients with high-grade, Bacillus Calmette-Guerin (BCG) refractory or relapsed non-muscle invasive bladder cancer: a phase II randomized study - Session Highlights

ASCO GU 2017: Options for the Patient Who Does Not Respond to Bacillus Calmette-Guérin When Radical Cystectomy Is Not an Option - Session Highlights

1
2
3
4
5